Drugs / Anoro
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06474039 | Oct 2024 → Jun 2026 overdue | chronic obstructive pulmonary disease | Mahidol University | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03527927 | May 2017 → Aug 2019 | chronic obstructive pulmonary disease | Hywel Dda Health Board | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT06282861 Comparator | Feb 2024 → Jan 2025 | chronic obstructive pulmonary disease | Fundacio Privada Mon Clinic Barcelona | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anoro | “The participants will choose: Ultibro® (Breezhaler device) or Duaklir® (Genuair device) or Anoro® (Ellipta device) or Spiolto® (Respimat device) and they will be prescribed the...” NCT03527927 ↗ |
| Route | Inhaled | “Both drugs delivered via Ellipta device and blinded package appearance” NCT06474039 ↗ |